Vermillion Announces First Quarter 2008 Financial Results and Busines...(d findings from an OSU clinical study th...)

SELDI-TOF-based TTP diagnostic test, which already has been

commercially launched as a laboratory developed test by the

institution, also could be used to help estimate the risk of TTP

relapses during clinical remission. The data -- published in the

online edition of the British Journal of Haematology -- indicate

that use of the test may provide a novel screening strategy to

identify patients who may benefit from prophylactic treatment to

help prevent relapse of this serious blood disorder.

-- Corporate Developments

* Appointed John F. Hamilton, former vice president and chief

financial officer of Depomed, Inc., to the Vermillion Board of

Directors and to serve as chairman of the Audit Committee of the

Board.

* Received issuance of U.S. Patent No. 7,341,838 for the discovery of

novel forms of brain natriuretic peptide (BNP), which could

potentially improve upon the current standard of care in diagnosing

and treating cardiovascular disease. The discovery could ultimately

lead to the development of an improved, next-generation assay that

might provide physicians with additional, valuable information to

stratify patients at risk for cardiovascular disease.

* Renewed a long-standing collaboration with Johns Hopkins University

on the development of novel biomarkers that can be applied toward

disease detection, classification and monitoring of prevalent

cancers, including ovarian, breast and prostate. Vermillion will

have access to exclusive commercial rights to the discoveries made

through the partnership.

* Vermillion's stockholders and board of directors approved a 1 for

'/>"/>